Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    tommy institut cancérologie
Previous Study | Return to List | Next Study

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse (TOMMY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01794572
Recruitment Status : Unknown
Verified August 2016 by Institut Cancerologie de l'Ouest.
Recruitment status was:  Recruiting
First Posted : February 20, 2013
Last Update Posted : August 31, 2016
Sponsor:
Information provided by (Responsible Party):
Institut Cancerologie de l'Ouest

Brief Summary:
In Multiple Myeloma, an adult hematological malignancy, mainly located in the Bone Marrow (BM), dramatic recent progresses have been observed, thanks to new agents (proteasome inhibitors and IMIDs). However, at time of first relapse, high-dose therapy followed by Stem Cell Rescue (SCR) is frequently mandatory as a consolidation in minimal residual disease, to healthy patients under 65 yo, combining Melphalan (MPH) and/or Total Body Irradiation. Modern irradiation modalities are now available by the use of HI-ART Tomotherapy system to realize a Total Bone Marrow Irradiation (TBMI), in order both to limit the dose administered to Organ at Risk (lungs, oral cavity) and to focus efficacy on BM. In this phase-1 study, the conditioning regimen before SCR will combine a fixed high-dose MPH (140 mg/m²) and a dose escalated TBMI, so as to define its Maximal Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT). An extended cohort will further in a phase-2 setting.

Condition or disease Intervention/treatment Phase
Multiple Myeloma in Relapse Drug: Melphalan Biological: Autologous Hematopoietic Stem cell Phase 1 Phase 2

Detailed Description:

Experimental :

Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a "3x3" modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.

Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.

Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day "0" after adequate premedication.

Despite the recent finding of new drugs (proteasome inhibitors and IMIDs), Multiple Myeloma still remain uncurable, especially after the first relapse, even in responding disease under conventional chemotherapy. In the healthy youngest patients (<65 yo), when peripheral stem cells collection is available, a high-dose therapy is often proposed in consolidation of complete or very good partial remission: the conditioning regimen usually includes high dose alkylating agent (mostly Melphalan) and/or Total Body Irradiation. The new Tomotherapy HI-ART technology allows irradiating on a 1.6m length field all the bone marrow sites together with optimal respect of the Organ at Risk (lungs, oral cavity, heart, liver, kidneys…). The proposed phase-1 study will explore the safety and efficacy of escalated dose of Total Bone-Marrow Irradiation in combination with a fixed dose of Melphalan (140mg/m²), followed by autologous SCR. To determine the MTD is the main objective of the study, then the toxicity profile (DLTs) and the RP2D in an extended cohort at the MTD dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.
Study Start Date : January 2013
Estimated Primary Completion Date : April 2017
Estimated Study Completion Date : October 2018


Arm Intervention/treatment
Experimental: Total BM irradiation dose

Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a "3x3" modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.

For Every patients:

Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.

Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day "0" after adequate premedication.

Drug: Melphalan
Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
Other Name: Phenylalanin Mustard

Biological: Autologous Hematopoietic Stem cell
Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day "0" after adequate premedication.
Other Name: Hematopoietic stem cell




Primary Outcome Measures :
  1. Maximal Tolerated Dose, type of DLTs [ Time Frame: 1 year ]
    Maximal Tolerated Dose Type of Dose-limiting Toxicities The escalated dose levels are determined according to a "3x3" modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.


Secondary Outcome Measures :
  1. Safety profile Recommended Dose for Phase-2 (RDP2) [ Time Frame: 1 year ]
    Safety profile: acute, short and middle term toxicities Recommended Dose for Phase-2 (RDP2) and Extended Cohort for 14 patients at this dose


Other Outcome Measures:
  1. Efficacy [ Time Frame: 1 and 2 years ]
    Bone-marrow control evaluation by FDG PET-Scan Disease-free survival at 1 year and Overall Survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Multiple Myeloma in first relapse.
  • In Complete or very good partial remission
  • Available Collected Autologous Peripheral Stem cells: 2.5x106 CD34+/Kg

Exclusion Criteria:

  • Uncontrolled visceral disease: kidney, heart, lung, diabetes mellitus
  • Previous Total body irradiation
  • Any previous radiation dose to the spinal cord which could reach to 45gy equivalent, including the proposed TBMI
  • Amyloidosis
  • Brain localizations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01794572


Contacts
Layout table for location contacts
Contact: Marc A MAHE, MD, PhD +33 240679900 marc-andre.mahe@ico.unicancer.fr
Contact: Francois JL PEIN, MD +33 240679908 francois.pein@ico.unicancer.fr

Locations
Layout table for location information
France
CLCC Bergonie, service de radiotherapie Not yet recruiting
Bordeaux, France, 33076
Contact: Benedicte Henriques de Figueiredo, MD    +33 556333366    b.henriques@bordeaux.unicancer.fr   
Principal Investigator: Benedicte Henriques de Figueriredo, MD         
CHU Haut-Leveque, service d'Hématologie Not yet recruiting
Bordeaux, France, 33604
Contact: Gerald Marit, MD, PhD    +33 556795679    gerald.marit@chu-bordeaux.fr   
Principal Investigator: Gerald Marit, MD, PhD         
CLCC Oscar Lambret, service de radiothérapie Recruiting
Lille, France, 59020
Contact: Eric Lartigau, MD, PhD    +33 320295911    e-lartigau@o-lambret.fr   
Principal Investigator: Eric Lartigau, MD, PhD         
CHU Claude Huriez, service d'hématologie Recruiting
Lille, France, 59037
Contact: Thierry Facon, MD, PhD    +33 320445962    thierry.facon@chru.lille.fr   
Principal Investigator: Thierry Facon, MD, PhD         
CLCC ICO, service de radiothérapie Recruiting
Nantes, St Herblain, France, 44805
Contact: Marc A Mahé, MD, PhD    +33 240679900    marc-andre.mahe@ico.unicancer.fr   
Principal Investigator: Marc A Mahé, MD, PhD         
CHU Hotel-Dieu, service d'hématologie Recruiting
Nantes, France, 44093
Contact: Philippe Moreau, MD, PhD    +33 240083260    philippe.moreau@chu-nantes.fr   
Principal Investigator: Philippe Moreau, MD, PhD         
CLCC Paul Strauss, service de radiothérapie Recruiting
Strasbourg, France, 67091
Contact: Georges Noel, MD, PhD    +33 88252478    gnoel@strasbourg.fr   
Principal Investigator: Gerard Noel, MD, PhD         
CHU Hautepierre, service d'hématologie Recruiting
Strasbourg, France, 67098
Contact: Bruno Lioure, MD, PhD    +33 88 127676    bruno.lioure@chru-strasbourg.fr   
Principal Investigator: Bruno Lioure, MD, PhD         
Sponsors and Collaborators
Institut Cancerologie de l'Ouest
Investigators
Layout table for investigator information
Principal Investigator: Marc A MAHE, MD, PhD Institut de Cancerologie de l'Ouest
Principal Investigator: Philippe MOREAU, MD, PhD University Hospital, CHU de NANTES
Publications:
Layout table for additonal information
Responsible Party: Institut Cancerologie de l'Ouest
ClinicalTrials.gov Identifier: NCT01794572    
Other Study ID Numbers: ICO-2012-04
2012-001473-91 ( EudraCT Number )
First Posted: February 20, 2013    Key Record Dates
Last Update Posted: August 31, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Institut Cancerologie de l'Ouest:
Multiple Myeloma
Relapse
Complete Remission
Very Good Partial Remission
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Recurrence
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Melphalan
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs